Abstract:Oral vaccination has in the recent years gained a lot of attraction, mainly due to optimized patient compliance and logistics. However, the development of oral vaccines, especially oral subunit vaccines is challenging. Micro technology can be utilized to overcome some of these challenges, by facilitating protection and effective delivery of the vaccine components in the gastrointestinal tract (GI tract). One such technology is Microcontainers (MCs), which can be realized to be mucoadhesive and to target specific regions of the GI tract via oral delivery. Here, we test MCs, for oral delivery of the C. trachomatis vaccine candidate CTH522, in combination with effective mucosal adjuvants. The adjuvants alpha- galactosylceramide (α-GalCer), C-di-GMP and cholera toxin B were compared in vivo, to identify the most prominent adjuvant for formulation with CTH522. Formulations were administered both purely oral and as boosters following a subcutaneous (s.c.) prime with CTH522 in combination with the CAF®01 adjuvant. CTH522 formulated with α-GalCer showed to be the most efficient combination for the oral vaccine, based on the immunological analysis. Lyophilized formulation of CTH522 and α-GalCer was loaded into MCs and these were subsequently coated with Eudragit L100-55 and evaluated in vivo in mice for the ability of MCs to mediate intestinal vaccine delivery and increase immunogenicity of the vaccine. Mice receiving oral prime and boosters did show a significantly enhanced mucosal immune responses compared to naive mice. This indicates the MCs are indeed capable of delivering the vaccine formulation intact and able to stimulate the immune cells. Mice orally boosted with MCs following a s.c. prime with CAF01, demonstrated improved systemic and local Th17 responses, along with increased local IFN-γ and IgA levels compared to both the s.c. prime alone and the homologous oral prime-boost immunization. However, due to the relatively weak observed effect of the MC delivery on the immune responses, it was hypothesized that the MCs are proportionally too large for the GI tract of mice, and thus cleared before an effective immune response can be induced. To investigate this, MCs were loaded with BaSO4, and orally administered to mice. Analysis with X-ray and CT showed a transit time of approximately 1-1.5 h from the stomach to the cecum, corresponding to the standard transit time in mice, and an extremely narrow absorption window. This indicates that mice is not a suitable animal model for evaluation of MCs. These data should be taken into consideration in future in vivo trials with this and similar technologies, where larger animals might be a necessity for proof-of-concept studies.

In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery.

Preparation of N-trimethyl chitosan-protein nanoparticles intended for vaccine delivery

Evaluation and modification of N-trimethyl chitosan chloride nanoparticles as protein carriers.

Enhancing Stability and Mucoadhesive Properties of Chitosan Nanoparticles by Surface Modification with Sodium Alginate and Polyethylene Glycol for Potential Oral Mucosa Vaccine Delivery

Cyclodextrin/chitosan nanoparticles for oral ovalbumin delivery: Preparation, characterization and intestinal mucosal immunity in mice

Chitosan Based Nanoparticles As Protein Carriers for Efficient Oral Antigen Delivery.

The Application of Chitosan-Based Nanocarrier for Oral Protein Drug/Vaccine Delivery

Eudragit® L100-coated mannosylated chitosan nanoparticles for oral protein vaccine delivery

Antigen-conjugated N-trimethylaminoethylmethacrylate Chitosan Nanoparticles Induce Strong Immune Responses after Nasal Administration

Preparation and evaluation of oleoyl-carboxymethy-chitosan (OCMCS) nanoparticles as oral protein carriers

Adjuvanted, antigen loaded N-trimethyl chitosan nanoparticles for nasal and intradermal vaccination: adjuvant- and site-dependent immunogenicity in mice

Preparation, intestinal segment stability, and mucoadhesion properties of novel thymopentin-loaded chitosan derivatives coated with poly (n-butyl) cyanoacrylate nanoparticles.

In vivo immunological activity of chitosan-derived nanoparticles

Preparation of Ovalbumin Nanoparticles with Trimethyl Chitosan Chloride

Oral vaccination using microdevices to deliver α-GalCer adjuvanted vaccine afford a mucosal immune response

Promotion of the Transdermal Delivery of Protein Drugs by N-trimethyl Chitosan Nanoparticles Combined with Polypropylene Electret.

Preparation and Evaluation of Antigen/n-Trimethylaminoethylmethacrylate Chitosan Conjugates for Nasal Immunization

Chitosan-alginate/R8 Ternary Polyelectrolyte Complex As an Oral Protein-Based Vaccine Candidate Induce Effective Mucosal Immune Responses

Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery.

N-trimethyl chitosan-modified liposomes as carriers for oral delivery of salmon calcitonin.

Preparation and Characterization of Folate Conjugated N-trimethyl Chitosan Nanoparticles As Protein Carrier Targeting Folate Receptor: in Vitro Studies.